Clinical trial
Phase II Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in Epidermolysis Bullosa.
NCT05288478 is registered in ClinicalTrials.gov with University of Chile as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in Epidermolysis Bullosa.
- Lead sponsor
- University of Chile
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 6, 2022
- Completion date
- March 31, 2023
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.